This is a technical overview of an INVAMED device within the oncology ablation portfolio. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy.
Peta Radiofrequency Ablation (RFA) System: Overview
Precision-engineered radiofrequency ablation device for minimally invasive tumor ablation, delivering controlled energy to treat soft tissue and liver tumors while minimizing damage to surrounding healthy tissue (per invamed.com content surfaced via search index). The 'Nerve' variant at the listed URL targets specific pain-transmitting nerves (facet joint pain, sacroiliac joint disorders, chronic back/neck pain) using RF energy to generate localized heat.
Technical Specifications
Specifications per INVAMED product documentation; confirm current details in the official IFU.
| Attribute | Detail |
|---|---|
| Specification | RF generator-based ablation platform |
| Specification | Variants for nerve (pain) ablation and soft tissue/liver tumor ablation |
How It Works and Where It Fits
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). Percutaneous thermal ablation relies on an applicator advanced through the skin to the tumor under imaging, so that energy is confined as much as possible to the target while sparing adjacent structures. Microwave ablation generates an oscillating electromagnetic field at the antenna tip that agitates water molecules, producing frictional heat that can create a cytotoxic ablation zone in seconds to minutes.
Key Considerations
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
Frequently Asked Questions
How is microwave ablation different from radiofrequency ablation?
Both are heat-based, but microwave ablation is often described as heating tissue faster and being less affected by the heat-sink effect near vessels, while RFA has a particularly deep evidence base; the choice is made by the clinician.
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
INVAMED's Peta Radiofrequency Ablation (RFA) System is a generator-based ablation platform offered in variants for soft-tissue and liver tumor ablation as well as nerve (pain) ablation, and the multi-application ThermoEdge RFA Platform is positioned for liver and kidney tissue resection, cysts, and endometrial ablation. Antenna gauge, active-tip length, and generator power (measured in watts) are the primary variables a clinician balances against the intended ablation zone size for a given lesion. MWA is frequently discussed for liver and lung tumors, but suitability, applicator selection, and power protocol are determined case by case by the interventional physician. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team.
Related on INVAMED
- Oncology Ablation — product category
- Choosing a Oncology Ablation Supplier: What Buyers Should Know
- What is the success rate of liver tumor ablation?
- What size tumor can be ablated (the 3 cm rule)?
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.